2 Top Biotech Stocks to Buy and Hold for 10 Years

Motley Fool2022-01-17

Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

366

Report

Comment（43）

alexchang
·2022-01-18
[Like] thks
Reply
Like
Report
Ac85
·2022-01-18
Thanks for sharing
Reply
Like
Report
JLKang
·2022-01-18
Good recommendation!
Reply
1
Report
SCLIEW
·2022-01-18
666
Reply
1
Report
HENRYCSC
·2022-01-18
Ok
Reply
1
Report
Jess261
·2022-01-18
Okay
Reply
1
Report
ARIESan
·2022-01-18
Not for me
Reply
1
Report
Kong06
·2022-01-18
👌
Reply
2
Report
Kaykay0930
·2022-01-18
Cool stuff
Reply
1
Report
time to eat
·2022-01-18
Just buy
Reply
5
Report
Success88
·2022-01-18
Great
Reply
4
Report
james_l
·2022-01-18
Need to see more on how they are expanding yo other businesses and not just covid.
Reply
11
Report
MHh
·2022-01-18
Too many pharmaceutical companies around. Need to look much much beyond covid 19related production and compare.
Reply
8
Report
Sunshine_2
·2022-01-18
OK
Reply
6
Report
Gladys8jk
·2022-01-18
Ok
Reply
3
Report
ericbqlee
·2022-01-18
🤔
Reply
4
Report
Desoupie
·2022-01-18
Like pls [Bless]
Reply
8
Report
InvisibleP
·2022-01-18
What price to enter?
Reply
4
Report
Kelvinphan
·2022-01-18
Pls like
Reply
5
Report
haircut
·2022-01-18
If the virus last for 10 years, will we be still around?
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2204773593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-17 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2204773593","market":"us","top_or_hot":-1,"title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","media":"Motley Fool","content":"<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","article_id":"2204773593","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","pubTimestamp":1642419504,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Both companies are involved in the fight against COVID-19.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BK4535":"淡马锡持仓","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","BNTX":"BioNTech SE","BK4551":"寇图资本持仓"},"translate_title":"2大生物科技股应买入并持有10年","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1,"REGN":1,"BNTX":0.82},"content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9004321080,"gmtCreate":1642513079686,"gmtModify":1676533717243,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"htmlText":"[Like]&nbsp;thks","listText":"[Like]&nbsp;thks","text":"[Like] thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004321080","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004956251,"gmtCreate":1642483720927,"gmtModify":1676533714733,"author":{"id":"4103856739942010","authorId":"4103856739942010","name":"Ac85","avatar":"https://static.itradeup.com/news/ec68755482dc97ee28d687571e7b68d6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4103856739942010","authorIdStr":"4103856739942010"},"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004956251","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004967626,"gmtCreate":1642478621972,"gmtModify":1676533714358,"author":{"id":"4094622337222610","authorId":"4094622337222610","name":"JLKang","avatar":"https://static.tigerbbs.com/33ab643c577c9cadc6055155d6382c3a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094622337222610","authorIdStr":"4094622337222610"},"htmlText":"Good recommendation!&nbsp;","listText":"Good recommendation!&nbsp;","text":"Good recommendation!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004967626","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004969555,"gmtCreate":1642476224088,"gmtModify":1676533714202,"author":{"id":"4092970777728640","authorId":"4092970777728640","name":"SCLIEW","avatar":"https://static.tigerbbs.com/5da553e4d3d35db75d1caae023ca8a03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4092970777728640","authorIdStr":"4092970777728640"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004969555","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004934667,"gmtCreate":1642470204079,"gmtModify":1676533713616,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004934667","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004994999,"gmtCreate":1642468140336,"gmtModify":1676533713234,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004994999","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004907909,"gmtCreate":1642466732045,"gmtModify":1676533713012,"author":{"id":"4087545408973980","authorId":"4087545408973980","name":"ARIESan","avatar":"https://static.tigerbbs.com/ab7b9364a4791173d66fbb5fda8ef925","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087545408973980","authorIdStr":"4087545408973980"},"htmlText":"Not for me&nbsp;","listText":"Not for me&nbsp;","text":"Not for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004907909","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004909300,"gmtCreate":1642465910025,"gmtModify":1676533712829,"author":{"id":"3581903045598734","authorId":"3581903045598734","name":"Kong06","avatar":"https://static.itradeup.com/news/5bf652419ffd9f97ce57f77494066d52","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581903045598734","authorIdStr":"3581903045598734"},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004909300","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004042814,"gmtCreate":1642464491618,"gmtModify":1676533712419,"author":{"id":"4096686644908450","authorId":"4096686644908450","name":"Kaykay0930","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4096686644908450","authorIdStr":"4096686644908450"},"htmlText":"Cool stuff&nbsp;","listText":"Cool stuff&nbsp;","text":"Cool stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004042814","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004055161,"gmtCreate":1642463612033,"gmtModify":1676533712162,"author":{"id":"3583412008066274","authorId":"3583412008066274","name":"time to eat","avatar":"https://static.tigerbbs.com/c3d6a537cecde2d1daeefa1dd8ff6f99","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3583412008066274","authorIdStr":"3583412008066274"},"htmlText":"Just buy","listText":"Just buy","text":"Just buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004055161","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004063578,"gmtCreate":1642460328916,"gmtModify":1676533711518,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4101948424484190","authorIdStr":"4101948424484190"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004063578","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004069989,"gmtCreate":1642460031248,"gmtModify":1676533711488,"author":{"id":"3563436875655076","authorId":"3563436875655076","name":"james_l","avatar":"https://static.tigerbbs.com/7960ea5c640db331ff2de0da32f6a611","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3563436875655076","authorIdStr":"3563436875655076"},"htmlText":"Need to see more on how they are expanding yo other businesses and not just covid.","listText":"Need to see more on how they are expanding yo other businesses and not just covid.","text":"Need to see more on how they are expanding yo other businesses and not just covid.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004069989","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004088456,"gmtCreate":1642459304455,"gmtModify":1676533711338,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"Too many pharmaceutical companies around. Need to look much much beyond covid 19related production and compare.","listText":"Too many pharmaceutical companies around. Need to look much much beyond covid 19related production and compare.","text":"Too many pharmaceutical companies around. Need to look much much beyond covid 19related production and compare.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004088456","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004088310,"gmtCreate":1642459250046,"gmtModify":1676533711377,"author":{"id":"4094271730114360","authorId":"4094271730114360","name":"Sunshine_2","avatar":"https://static.tigerbbs.com/c51036e171ef144f127d28c64446c582","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094271730114360","authorIdStr":"4094271730114360"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004088310","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004081571,"gmtCreate":1642459163224,"gmtModify":1676533711315,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004081571","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004083285,"gmtCreate":1642459008203,"gmtModify":1676533711275,"author":{"id":"4101424154342900","authorId":"4101424154342900","name":"ericbqlee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4101424154342900","authorIdStr":"4101424154342900"},"htmlText":"🤔","listText":"🤔","text":"🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004083285","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004083012,"gmtCreate":1642458913944,"gmtModify":1676533711267,"author":{"id":"4088779006345160","authorId":"4088779006345160","name":"Desoupie","avatar":"https://static.tigerbbs.com/61605302726ca838436e74d61cb437ae","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4088779006345160","authorIdStr":"4088779006345160"},"htmlText":"Like pls [Bless]&nbsp;","listText":"Like pls [Bless]&nbsp;","text":"Like pls [Bless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004083012","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":697682417,"gmtCreate":1642458734737,"gmtModify":1676532594024,"author":{"id":"3585470994468822","authorId":"3585470994468822","name":"InvisibleP","avatar":"https://static.itradeup.com/news/13510d2c4ac014319931fb49792d17eb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585470994468822","authorIdStr":"3585470994468822"},"htmlText":"What price to enter?&nbsp;","listText":"What price to enter?&nbsp;","text":"What price to enter?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/697682417","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9004080473,"gmtCreate":1642458728922,"gmtModify":1676533711243,"author":{"id":"3579053062900901","authorId":"3579053062900901","name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579053062900901","authorIdStr":"3579053062900901"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004080473","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004080303,"gmtCreate":1642458495834,"gmtModify":1676533711180,"author":{"id":"4102455619608180","authorId":"4102455619608180","name":"haircut","avatar":"https://static.tigerbbs.com/664eac8e1f74f7555d093f964e7bab93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4102455619608180","authorIdStr":"4102455619608180"},"htmlText":"If the virus last for 10 years, will we be still around?&nbsp;","listText":"If the virus last for 10 years, will we be still around?&nbsp;","text":"If the virus last for 10 years, will we be still around?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004080303","repostId":2204773593,"repostType":4,"repost":{"id":"2204773593","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","REGN":"再生元制药公司","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":366,"commentSize":43,"repostSize":0,"favoriteSize":9,"likeStatus":false,"favoriteStatus":false}}